What to Eat on GLP-1 Medications Like Ozempic and Wegovy (Full Guide)

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most significant shift in obesity and metabolic medicine in a generation. In the STEP 1 trial, semaglutide produced a mean weight loss of 14.9% over 68 weeks ^[1]; SURMOUNT-1 showed up to 20.9% with tirzepatide ^[2]. But the medication only does half the work — what you eat on a GLP-1 determines whether the weight you lose is fat or muscle, and whether the results last after you stop.

How GLP-1s actually change eating

GLP-1 agonists slow gastric emptying, amplify post-meal satiety signaling, and reduce hedonic 'food noise' through central appetite circuits ^[3]. The practical consequences are smaller meals, earlier fullness, lower interest in highly palatable foods, and — without intentional planning — a steep drop in total protein and micronutrient intake.

The three nutrition risks no one warns you about

• Lean mass loss: DEXA sub-studies of STEP 1 found that roughly 25–40% of weight lost on semaglutide came from lean mass when protein intake and resistance training were inadequate ^[4].
• Micronutrient gaps: smaller meals mean less iron, B12, calcium, vitamin D, and fiber unless you're intentional — particularly relevant given documented dose-dependent reductions in total caloric intake.
• Rebound weight gain: in the STEP 1 extension trial, participants regained two-thirds of lost weight within a year of stopping semaglutide ^[5]. Muscle is your metabolic engine — losing it lowers resting metabolism and makes regain easier.

Daily targets at a glance

The daily framework

1. Anchor every meal in protein

Aim for 1.2–1.6 g of protein per kg of body weight per day during active weight loss — the range supported by ISSN position statements ^[6] and replicated in obesity-treatment trials for muscle preservation. Front-load earlier when appetite is highest. Practically, that's 30–40 g of protein at breakfast, lunch, and dinner. Greek yogurt, eggs, cottage cheese, chicken, fish, tofu, tempeh, and lean beef are the workhorses. A protein shake counts when food won't fit.

2. Don't skip fiber — it prevents the GI side effects

Constipation, bloating, and nausea are the most common reasons people stop GLP-1s ^[7]. Soluble fiber from oats, chia, beans, berries, kiwi, and psyllium softens stools and feeds the gut microbiome. Target 25–35 g per day (Institute of Medicine DRI), increased gradually with plenty of water.

3. Eat color and healthy fats for micronutrient density

Half your plate should be non-starchy vegetables. Add olive oil, avocado, nuts, and fatty fish for absorption of fat-soluble vitamins (A, D, E, K). When meals are smaller, density matters more than volume.

4. Hydrate like it's part of the prescription

Reduced thirst is a quiet side effect. Aim for half your body weight in ounces of water, more if you're active. Electrolytes help on lower-carb days, and adequate fluid is the single biggest mitigator of the acute kidney injury signal that shows up in pharmacovigilance data ^[8].

A sample day on a GLP-1

Lift heavy things, two to three times per week

Resistance training is non-negotiable on a GLP-1. A 2024 trial in NEJM found that combining semaglutide with supervised exercise preserved lean mass and improved cardiorespiratory fitness in ways the drug alone did not ^[9]. Two to three sessions per week of compound movements (squats, presses, rows, hinges) is enough to dramatically reduce lean mass loss.

What we still don't know — and how to plan for it

The long-term (5+ year) data on GLP-1s in non-diabetic weight management is still maturing. What is clear from STEP and SURMOUNT is that most weight is regained within a year of discontinuation if eating patterns and resistance training haven't been rebuilt ^[5]. Plan from day one as if the medication is scaffolding, not a permanent floor — protein, lifting, fiber, and sleep are the structures that hold up after the scaffolding comes down.

A note on hydration, electrolytes, and the kidneys

Rapid weight loss and reduced fluid intake can transiently raise creatinine and stress the kidneys. A pharmacovigilance signal for acute kidney injury during GLP-1 initiation — primarily mediated by dehydration from nausea/vomiting — has been replicated across FDA AERS analyses ^[8]. People with CKD should have eGFR and electrolytes monitored more often during titration, and should avoid combining GLP-1s with NSAIDs or dehydration without clinician input.